Bispecific T-cell engagers developed for blood cancers are being repurposed to eliminate pathogenic B cells and plasma cells in severe autoimmune disease, potentially offering CAR-T-like depth without individualized cell manufacturing.
Find out how Qihan Biotech’s QT-019B FDA designations could reshape autoimmune CAR-T development and what risks remain.
Find out how Minghui Pharmaceutical’s MHB018A could reshape thyroid eye disease treatment as Phase III trials test its promise.
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.
Find out how Cartesian Therapeutics’ WestGene deal could reshape in vivo CAR-T strategy in autoimmune disease and what risks remain.
See how Johnson & Johnson’s nipocalimab data could reshape lupus and Sjögren’s disease treatment strategy today!
Find out how Antengene’s ATG-207 data could shape autoimmune drug development as CD3 and TGF-beta fusion biology enters focus.
Bispecific antibodies are moving beyond oncology. Innovent’s autoimmune pipeline now faces the harder test of clinical durability.
Atopic dermatitis has more drugs, but not enough durable control. TRexBio’s TRB-061 tests whether tissue Tregs can change that.
Can AlloNK make autoimmune cell therapy scalable? Explore why Artiva Biotherapeutics, Inc.’s rheumatoid arthritis strategy matters.